About: Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.89 (+2.53%)
TVRD NASDAQ Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. share price
TVRD price activity
Last Price
$0.890
Change (24hr)
0.02 USD (2.53%)
Volume
86.03K
Volume (4w avg)
-
Open
$0.86
Day Range
$0.86 - $0.93
Previous Close
$0.87
Last Trade
28 Oct, 8:00 pm GMT+0
Delayed
28 Oct, 8:00 pm GMT+0
TVRD price performance
Delayed
28 Oct, 8:00 pm GMT+0
TVRD Market Signals